restasis multidose Drug Patent Profile
✉ Email this page to a colleague
When do Restasis Multidose patents expire, and what generic alternatives are available?
Restasis Multidose is a drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-three patent family members in twenty-six countries.
The generic ingredient in RESTASIS MULTIDOSE is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Restasis Multidose
A generic version of restasis multidose was approved as cyclosporine by HIKMA on October 29th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for restasis multidose?
- What are the global sales for restasis multidose?
- What is Average Wholesale Price for restasis multidose?
Summary for restasis multidose
International Patents: | 63 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 5 |
Clinical Trials: | 51 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for restasis multidose |
What excipients (inactive ingredients) are in restasis multidose? | restasis multidose excipients list |
DailyMed Link: | restasis multidose at DailyMed |
![restasis multidose drug patent expirations Drug patent expirations by year for restasis multidose](/p/graph/s/t/restasis_multidose-patent-expirations.png)
![Drug Prices for restasis multidose](/p/graph/drug-price/restasis+multidose.png)
Recent Clinical Trials for restasis multidose
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
OphRx Ltd. | Early Phase 1 |
Boston Sight | Phase 1/Phase 2 |
Allergan | Phase 1/Phase 2 |
Pharmacology for restasis multidose
Drug Class | Calcineurin Inhibitor Immunosuppressant |
Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
Paragraph IV (Patent) Challenges for RESTASIS MULTIDOSE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RESTASIS MULTIDOSE | Ophthalmic Emulsion | cyclosporine | 0.05% | 050790 | 1 | 2014-01-13 |
US Patents and Regulatory Information for restasis multidose
restasis multidose is protected by ten US patents.
Patents protecting restasis multidose
Dispensing device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dispensing device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of providing therapeutic effects using cyclosporin components
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | RESTASIS MULTIDOSE | cyclosporine | EMULSION;OPHTHALMIC | 050790-002 | Oct 27, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Abbvie | RESTASIS MULTIDOSE | cyclosporine | EMULSION;OPHTHALMIC | 050790-002 | Oct 27, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Abbvie | RESTASIS MULTIDOSE | cyclosporine | EMULSION;OPHTHALMIC | 050790-002 | Oct 27, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for restasis multidose
See the table below for patents covering restasis multidose around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 1335566 | COMPOSITION OPHTALMIQUE A BASE DE CYCLOSPORINE (OCULAR CYCLOSPORIN COMPOSITION) | ⤷ Sign Up |
Hong Kong | 1034190 | ⤷ Sign Up | |
Denmark | 3083431 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for restasis multidose
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049079 | LUC00006 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |